Compile Data Set for Download or QSAR
Report error Found 1006 Enz. Inhib. hit(s) with all data for entry = 11473
TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618729(US20230293517, Example 4.7)
Affinity DataKi:  0.0500nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618748(US20230293517, Example 4.26)
Affinity DataKi:  0.0500nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618966(US20230293517, Example 28 | N-[5-[2,6-Bis(trideute...)
Affinity DataKi:  0.0900nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618717(US20230293517, Example 3.8)
Affinity DataKi:  0.0900nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618952(US20230293517, Example 16.9)
Affinity DataKi:  0.100nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618749(US20230293517, Example 4.27)
Affinity DataKi:  0.100nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618744(US20230293517, Example 4.22)
Affinity DataKi:  0.100nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618723(US20230293517, Example 4.1 | 4-Cyano-N-[4-(3-cyano...)
Affinity DataKi:  0.110nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618777(US20230293517, Example 6.7)
Affinity DataKi:  0.110nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618747(US20230293517, Example 4.25)
Affinity DataKi:  0.120nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618770(US20230293517, Example 6 | 4-Cyano-N-[4-(3-cyanoph...)
Affinity DataKi:  0.120nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618950(US20230293517, Example 16.7)
Affinity DataKi:  0.130nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618751(US20230293517, Example 4.29)
Affinity DataKi:  0.130nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618951(US20230293517, Example 16.8)
Affinity DataKi:  0.130nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618947(US20230293517, Example 16.4)
Affinity DataKi:  0.130nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618869(US20230293517, Example 6.99)
Affinity DataKi:  0.130nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618731(US20230293517, Example 4.9)
Affinity DataKi:  0.140nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618965(US20230293517, Example 27b | (3S)-3-cyano-N-[4-(3-...)
Affinity DataKi:  0.140nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618790(US20230293517, Example 6.20)
Affinity DataKi:  0.140nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618834(US20230293517, Example 6.64)
Affinity DataKi:  0.140nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618754(US20230293517, Example 4.32)
Affinity DataKi:  0.150nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618949(US20230293517, Example 16.6)
Affinity DataKi:  0.160nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618914(US20230293517, Example 12 | 4-Cyano-N-[4-(3-cyanop...)
Affinity DataKi:  0.160nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618870(US20230293517, Example 6.100)
Affinity DataKi:  0.160nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618960(US20230293517, Example 23 | N-[5-[2-Chloro-6-(1-hy...)
Affinity DataKi:  0.160nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618746(US20230293517, Example 4.24)
Affinity DataKi:  0.180nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618811(US20230293517, Example 6.41)
Affinity DataKi:  0.180nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618918(US20230293517, Example 12.3b | N-[4-(3-Cyanophenyl...)
Affinity DataKi:  0.180nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618934(US20230293517, Example 13.14)
Affinity DataKi:  0.180nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618728(US20230293517, Example 4.6)
Affinity DataKi:  0.180nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618959(US20230293517, Example 22 | N-[4-(3-Cyanophenyl)-5...)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618915(US20230293517, Example 12.1 | N-[4-(3-Cyanophenyl)...)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618745(US20230293517, Example 4.23)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618874(US20230293517, Example 6.104)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618716(US20230293517, Example 3.7)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618881(US20230293517, Example 6.111)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618891(US20230293517, Example 7.2 | 4-Amino-4-cyano-N-[4-...)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618958(US20230293517, Example 21 | N-[4-(3-Cyanophenyl)-5...)
Affinity DataKi:  0.210nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618782(US20230293517, Example 6.12)
Affinity DataKi:  0.230nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618867(US20230293517, Example 6.97)
Affinity DataKi:  0.230nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618962(US20230293517, Example 26 | N-[4-(3-Cyanophenyl)-5...)
Affinity DataKi:  0.240nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618961(US20230293517, Example 24 | 4-Cyano-N-[4-(3-cyanop...)
Affinity DataKi:  0.240nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618721(US20230293517, Example 3.12)
Affinity DataKi:  0.25nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618880(US20230293517, Example 6.110)
Affinity DataKi:  0.260nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618734(US20230293517, Example 4.12 | N-[4-(3-Cyanophenyl)...)
Affinity DataKi:  0.260nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618823(US20230293517, Example 6.53)
Affinity DataKi:  0.270nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618724(US20230293517, Example 4.2)
Affinity DataKi:  0.270nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618916(US20230293517, Example 12.2 | N-[4-(3-Cyanophenyl)...)
Affinity DataKi:  0.280nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618944(US20230293517, Example 16.1)
Affinity DataKi:  0.290nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM618743(US20230293517, Example 4.21)
Affinity DataKi:  0.300nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1×LabMed (Cisbio, France...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

Displayed 1 to 50 (of 1006 total ) | Next | Last >>
Jump to: